KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, today announced the signing of a second plasma supply agreement. Under this second agreement, DCI Biologicals, Inc. will collect plasma from Vitiligo donors for the manufacture of VitiGam™, GammaCan’s lead product in development for the treatment of Stage III and IV melanoma.
